Systemic, nasal and oral live vaccines against Pseudomonas aeruginosa: A clinical trial of immunogenicity in lower airways of human volunteers

Mucosal and systemic antibody responses to potentialPseudomonas aeruginosavaccine protein antigens in young children with cystic fibrosis following colonization and infection

“…The order of the antigen specific IgG membrane proteins (Oprs), F (OprF) and I (OprI), are lead vaccine candidate antigens. [15][16][17] Preventing P. aeruginosa infection by vaccinating CF patients has been a goal for many years, but despite numerous animal studies and several human trials, an efficacious vaccine for P. aeruginosa remains elusive. [18][19][20] Several P. aeruginosa antigens invoke the characteristic rise in antibody titers as the disease state progresses and can be detected in the sera, sputa, saliva, tears and bronchoalveolar lavage (BAL) fluid from CF patients.…”

A randomized, placebo-controlled phase I study assessing the safety and immunogenicity of aPseudomonas aeruginosahybrid outer membrane protein OprF/I vaccine (IC43) in healthy volunteers

“…Although the results of several attempts to develop a vaccine have been published, no P. aeruginosa vaccine is available. 5,[8][9][10][11][12][13] In gram-negative bacteria lipopolysaccharides and outer membrane proteins are the major antigenic components of the bacterial envelope. Because lipopolysaccharide-based vaccines might cause systemic adverse reactions, 14 due to systemic inflammation after parenteral injection, 7 outer membrane protein-based vaccines with an acceptable toxicity profile are attractive clinical development candidates.…”

Vaccine strategies against bacterial pathogens in cystic fibrosis patients

“…They are both outer membrane proteins able to induce a specific antibody response in the lungs after nasal or oral vaccination. Both of these proteins are good candidates for a P. aeruginosa vaccine [38]. A fusion protein from a part of P. aeruginosa OprF, OprI, and FliC helped in P. aeruginosa clearance in a pulmonary challenge model [39].…”